Literature DB >> 21640504

Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.

Adeline Lim1, Serena Sia.   

Abstract

PURPOSE: A retrospective review of patients with Stage IB1-IVA cervical cancer treated with combined chemoradiotherapy in Western Australia was conducted with the aim of assessing outcomes and patterns of recurrence. Multivariate analysis was performed to identify potential prognostic factors. METHODS AND MATERIALS: Patients treated with radical chemoradiotherapy for cervical cancer in Western Australia between June 2005 and November 2008 were analyzed. Treatment consisted of external-beam radiotherapy with concurrent weekly cisplatin (40 mg/m(2)), followed by high-dose-rate brachytherapy. The Kaplan-Meier method was used to determine overall survival and disease-free survival, and Cox regression analysis was used to identify potential prognostic factors.
RESULTS: Sixty-nine patients were included in the analysis. All patients completed external-beam radiotherapy; however, only 43.5% of patients completed the planned course of brachytherapy. At a median follow-up of 27 months, 24- and 48-month overall survival were 68.8% and 61.1%, respectively. Disease-free survival at 24 and 48 months was 59.4% and 56.7%, respectively. The 2-year local control rate was 70.1%. Nodal involvement resulted in increased risk of disease recurrence (hazard ratio [HR] 6.26, p = 0.002) and death (HR 5.15, p = 0.013). Pretreatment hemoglobin <120 g/L was a negative prognostic factor for disease recurrence (HR 4.20, p = 0.031) and death (HR 8.19, p = 0.020). Completion of brachytherapy improved overall survival (p = 0.039), with a trend to reducing disease recurrence (p = 0.052). The risk of relapse increased with treatment time over 8 weeks (HR 8.18, p = 0.019), however treatment time did not affect the risk of death (p = 0.245).
CONCLUSION: The overall survival outcomes in this group of women with locally advanced cervical carcinomas treated with chemoradiotherapy are comparable to worldwide data. Despite the use of modern treatment protocols, a significant proportion of women developed locoregional recurrences and distant failures. Many poor prognostic factors have been identified as contributors to this, including pelvic nodal involvement, incomplete brachytherapy, pretreatment hemoglobin <120 g/L, and treatment time over 8 weeks. Crown Copyright Â
© 2012. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21640504     DOI: 10.1016/j.ijrobp.2011.04.047

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

Review 1.  Radiobiological considerations in combining doses from external beam radiotherapy and brachytherapy for cervical cancer.

Authors:  Ana M Tornero-López; Damián Guirado
Journal:  Rep Pract Oncol Radiother       Date:  2018-07-02

2.  Impact of Human Immunodeficiency Virus Infection on Survival and Acute Toxicities From Chemoradiation Therapy for Cervical Cancer Patients in a Limited-Resource Setting.

Authors:  Surbhi Grover; Memory Bvochora-Nsingo; Alyssa Yeager; Sebathu Chiyapo; Rohini Bhatia; Emily MacDuffie; Priya Puri; Dawn Balang; Sarah Ratcliffe; Mohan Narasimhamurthy; Elliphine Gwangwava; Sylvia Tsietso; Mukendi K A Kayembe; Doreen Ramogola-Masire; Scott Dryden-Peterson; Umesh Mahantshetty; Akila N Viswanathan; Nicola M Zetola; Lilie L Lin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-02-01       Impact factor: 7.038

3.  Clinical Impact of Pelvic Lymph Node Status in Locally Advanced Cervical Cancer Patients Treated by Concurrent Chemoradiation Therapy.

Authors:  Kanyarat Katanyoo; Thaovalai Thavaramara
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

4.  Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.

Authors:  Masateru Fujiwara; Fumiaki Isohashi; Seiji Mabuchi; Yasuo Yoshioka; Yuji Seo; Osamu Suzuki; Iori Sumida; Kazuhiko Hayashi; Tadashi Kimura; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2014-11-26       Impact factor: 2.724

5.  Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort.

Authors:  Daisuke Endo; Yukiharu Todo; Kazuhira Okamoto; Shinichiro Minobe; Hidenori Kato; Noriaki Nishiyama
Journal:  J Gynecol Oncol       Date:  2014-10-13       Impact factor: 4.401

6.  The Neutrophil-Lymphocyte Ratio Predicts Recurrence of Cervical Intraepithelial Neoplasia.

Authors:  Sungwook Chun; Kyusik Shin; Ki Hyung Kim; Heung Yeol Kim; Wankyu Eo; Ji Young Lee; Jeong Namkung; Sang Hoon Kwon; Suk Bong Koh; Hong-Bae Kim
Journal:  J Cancer       Date:  2017-07-15       Impact factor: 4.207

7.  Carbon-ion radiotherapy for locally advanced cervical cancer with bladder invasion.

Authors:  Shintaro Shiba; Masaru Wakatsuki; Shingo Kato; Tatsuya Ohno; Noriyuki Okonogi; Kumiko Karasawa; Hiroki Kiyohara; Hirohiko Tsujii; Takashi Nakano; Tadashi Kamada; Makio Shozu
Journal:  J Radiat Res       Date:  2016-07-15       Impact factor: 2.724

8.  Concurrent chemoradiotherapy for cervical cancer: background including evidence-based data, pitfalls of the data, limitation of treatment in certain groups.

Authors:  Yukiharu Todo; Hidemichi Watari
Journal:  Chin J Cancer Res       Date:  2016-04       Impact factor: 5.087

9.  Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1/2 clinical trial (Protocol 1001).

Authors:  Noriyuki Okonogi; Masaru Wakatsuki; Shingo Kato; Kumiko Karasawa; Hiroki Kiyohara; Shintaro Shiba; Daijiro Kobayashi; Takashi Nakano; Tadashi Kamada; Makio Shozu
Journal:  Cancer Med       Date:  2018-01-17       Impact factor: 4.452

10.  The incidence and risk factors of acute radiation-induced dermatitis in gynecologic malignancies treated with intensity-modulated radiation therapy.

Authors:  Zhiqin Fu; Conghui Wang; Jianhong Chen; Yingchang Wang; Xiang Zhang
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.